


PHARMACEUTICAL 2022



Vaccitech plc Rank 111 of 475





PHARMACEUTICAL 2022



Vaccitech plc Rank 111 of 475

The relative strengths and weaknesses of Vaccitech plc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Vaccitech plc compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 104% points. The greatest weakness of Vaccitech plc is the variable Revenues, reducing the Economic Capital Ratio by 38% points.

The company's Economic Capital Ratio, given in the ranking table, is 36%, being 313% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	226,765
Cost of Goods Sold	0
Intangible Assets	44,060
Liabilities, Current	11,158
Liabilities, Non-Current	6,540
Other Assets	8,061
Other Compr. Net Income	-6,998
Other Expenses	-28
Other Liabilities	10,455
Other Net Income	-5,919
Property and Equipment	1,829
Research and Development	20,371
Revenues	268
Selling, General and Administrative Expense	25,118

Output Variable	Value in 1000 USD
Assets	280,715
Liabilities	28,153
Expenses	45,461
Stockholders Equity	252,562
Net Income	-51,112
Comprehensive Net Income	-54,611
Economic Capital Ratio	36%